 |
| “Overall, both of these reviews reaffirmed the vaccine offers a high level of protection against mild, moderate and severe forms of COVID-19 and that these benefits continue to far outweigh the risks,” the company added. (Photo from Johan NILSSON/TT NEWS AGENCY/AFP) |
[Asia News Communication = Reporter Reakkana] MANILA — Citing reviews from the United Kingdom (UK)’s Medicines and Healthcare Products Regulatory Agency (MHRA) and European Medicines Agency (EMA), AstraZeneca said yesterday that its COVID-19 vaccines offer a “high level of protection” against the virus, PhilStar said.
“Overall, both of these reviews reaffirmed the vaccine offers a high level of protection against mild, moderate, and severe forms of COVID-19 and that these benefits continue to far outweigh the risks,” the company added. AstraZeneca said both MHRA and EMA have completed their assessment of “extremely rare blood clotting events with low platelets from over 34 million people vaccinated” in the UK and EU. The company noted that both agencies did not identify any risk factor as a definite cause for these “extremely rare events.”
AstraZeneca said it is collaborating with regulators to understand individual cases, epidemiology and possible mechanisms that could explain these extremely rare events.
